That said, folks who don't need the absolute best or want to save up for a better solution should find these to be sufficient -- we didn't have a chance to do any in-depth testing and analysis, but expect that to come after we've had a chance to digest all of today's new gadgets.
Exclude those patients, and prasugrel looks better, but that analysis was done after the fact, which could raise doubts with the FDA. Lilly is testing a lower dose in those patients going forward.